CI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cigna Group (CI) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. The stock is currently experiencing bearish technical indicators, lacks positive proprietary trading signals, and has mixed financial performance. While analysts maintain positive long-term ratings, recent financial results and congressional selling activity suggest caution. Holding off on buying until clearer positive momentum emerges is advisable.
The technical indicators for CI are bearish. The MACD is negatively expanding (-0.802), the RSI is at 37.332 (neutral but nearing oversold territory), and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 282.98, with key support at 275.135 and resistance at 290.825.
Analysts maintain positive ratings with price targets ranging from $303 to $375, citing long-term growth potential from the company's rebate-free PBS model and 2026 guidance.
AM Best reaffirmed Cigna's Financial Strength Rating at A (Excellent), highlighting its strong balance sheet and stable performance.
Recent financial performance shows declining net income (-13.34% YoY), EPS (-11.31% YoY), and gross margin (-10.65% YoY) in Q4
Congress members have made 4 sale transactions in the last 90 days, indicating cautious sentiment.
Technical indicators are bearish, and the stock is trading below key support levels.
In Q4 2025, Cigna's revenue increased by 10.39% YoY to $72.47 billion. However, net income dropped by 13.34% YoY to $1.23 billion, EPS declined by 11.31% YoY to $4.55, and gross margin fell by 10.65% YoY to 8.22%. These mixed results reflect revenue growth but declining profitability.
Analysts maintain a generally positive outlook on CI, with multiple firms raising price targets recently. Piper Sandler, Truist, UBS, and others highlight long-term growth potential from the company's PBS model and 2026 guidance. However, Cantor Fitzgerald notes potential headwinds in the healthcare insurance sector due to political influences on Medicare Advantage rates.
